Trial Profile
STEM-AMI OUTCOME TRIAL STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial STEM-AMI OUTCOME TRIAL
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Left ventricular dysfunction; Myocardial infarction
- Focus Therapeutic Use
- Acronyms STEM-AMI Outcome
- 10 Mar 2022 Status changed from recruiting to discontinued.
- 01 Jul 2014 New trial record